Physician profile
John Bloom
NPI 1780656371
$4,473.87
in general payments reported to CMS, 2019-2025
25 companies · $839 in 2025
The $839 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $313 · 2021: $637 · 2022: $496 · 2023: $657 · 2024: $1,201 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Gift: $245 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.31 |
| Gift | $245.43 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,190.59 | 2019-2025 | Linzess, Mavyret, Viberzi |
| Celgene Corporation | $481.36 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $318.19 | 2023-2025 | Voquezna |
| Braintree Laboratories, INC. | $279.13 | 2020-2024 | Suflave, Sutab |
| Pfizer INC. | $273.73 | 2024-2025 | |
| Gilead Sciences, INC. | $244.37 | 2019-2022 | |
| Lilly USA, LLC | $199.82 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.11 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Ipsen Biopharmaceuticals, INC | $158.88 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $153.93 | 2020-2024 | Talicia, Aemcolo |
| E.R. Squibb & Sons, L.L.C. | $140.76 | 2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $138.74 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $128.57 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $120.65 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $115.99 | 2021-2023 | Dificid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $101.44 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $59.21 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $58.10 | 2024-2025 | Eohilia, Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.17 | 2023 | Cyltezo |
| Micro-Tech Endoscopy USA, INC. | $21.69 | 2022 | |
| Intercept Pharmaceuticals, INC. | $17.61 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.82 | 2021 | |
| Exact Sciences Corporation | $16.67 | 2025 | Cologuard Collection Kit |
| Vivus LLC | $14.30 | 2025 | Pancreaze |
| Organon LLC | $14.04 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.